Loading organizations...
§ Private Profile · San Francisco, CA, USA
Clinical-stage biotechnology company developing non-opioid therapeutics for post-surgical and chronic pain, addressing pain at its molecular roots.
Adynxx is a clinical-stage biotechnology company developing non-opioid therapeutics to address post-surgical and chronic pain syndromes, based in San Francisco, California. The publicly traded enterprise operates on the OTC markets under the ticker ADYX and utilizes its proprietary AYX platform to target pain at its molecular roots instead of treating symptoms. The firm's clinical pipeline includes its lead therapeutic candidate brivoligide, also known as AYX1, which previously completed enrollment for a Phase 2 clinical study designated ADYX-004. This treatment aims to prevent pain development with a single administration, positioning the firm within the broader health technology and biopharmaceutical sectors. Corporate leadership includes President and Chief Executive Officer Rick Orr, alongside Chairman Dennis Podlesak, who guide the strategic direction of the venture-backed business following its May 2019 public merger. Adynxx was founded in 2007 by Julien Mamet.
Adynxx has raised $16.0M across 1 funding round.
Adynxx has raised $16.0M in total across 1 funding round.
Adynxx has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series B in January 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2017 | $16M Series B | Heath Lukatch | Creacion Ventures, MPM Capital, RED Tree Venture Capital, Domain Associates | Announced |
Adynxx has raised $16.0M in total across 1 funding round.
Adynxx's investors include Heath Lukatch, Creacion Ventures, MPM Capital, Red Tree Venture Capital, Domain Associates.
Adynxx, Inc. is a clinical-stage biopharmaceutical company developing transcription factor decoy technologies, primarily the AYX platform, to create non-opioid therapeutics for pain and inflammatory diseases. It focuses on products like brivoligide (AYX1) for reducing postoperative pain and preventing its transition to chronic pain, and AYX2 for focal chronic pain, addressing unmet needs in pain management.[1][2][3] Headquartered in San Francisco, California, Adynxx serves patients and healthcare providers by targeting pain at its molecular roots through disease-modifying therapies, with collaborations in AI-driven drug discovery and licensing to expand its pipeline.[2][5] As a private company formerly known as Alliqua BioMedical after a 2018 merger, it remains in development without disclosed revenue or marketed products.[2][5]
Adynxx was founded in 2007 by Dr. Julien M......, a neuroscience and drug discovery expert who invented the AYX technology platform and serves as Chief Scientific Officer and board member.[1][3] The idea emerged from his extensive pharmaceutical background, including roles at Alliance Pharmaceutical, Neurocrine Biosciences, NovaCardia (acquired by Merck), and leadership in clinical operations for studies acquired by Novartis.[3] Early traction included advancing AYX1 (brivoligide) to Phase II for postoperative pain and building a pipeline for chronic conditions.[1][3][6] A pivotal moment came in 2018 with a merger with Alliqua BioMedical, making Adynxx stockholders the majority owners and reorienting the combined entity toward its pain-focused biotech mission.[2][5] Leadership evolved with figures like Richard Orr as President, CEO, and Principal Financial Officer since 2010.[1]
Adynxx stands out in biopharma through its novel approach to pain treatment:
Adynxx rides the wave of non-opioid pain therapeutics amid the global opioid epidemic and demand for innovative biotech solutions. Its timing aligns with post-2020 regulatory pushes for alternatives to addictive analgesics, heightened by chronic pain affecting millions and inflammation-linked diseases.[2][5] Market forces favoring it include AI-drug discovery collaborations accelerating pipelines and growing investment in precision medicine for neurology.[2] By influencing the ecosystem through discontinued-but-insightful trials (e.g., Phase II brivoligide) and pending programs in neuralgia/endometriosis, Adynxx contributes to biotech's shift toward molecularly targeted, non-addictive interventions, potentially licensing tech to larger players.[6]
Adynxx's path forward hinges on reviving or licensing its AYX platform amid discontinued lead programs, capitalizing on AI partnerships and non-opioid trends. Trends like precision therapeutics and regulatory incentives for pain innovation could propel pipeline candidates (e.g., KLF inhibitors for neuralgia) toward new trials or deals.[2][6] Its influence may evolve via acquisitions or collaborations, mirroring past biotech mergers, positioning it as a specialized player in inflammation/pain biotech rather than a standalone commercializer. This molecular-rooted approach, born from founder ingenuity, underscores Adynxx's potential to reshape pain management if execution aligns with market momentum.[1][3][5]